These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 39250819)

  • 1. Dual effects of targeting neuropilin-1 in lenvatinib-resistant hepatocellular carcinoma: inhibition of tumor growth and angiogenesis.
    Ao J; Qiang N; Kanzaki H; Nakamura M; Kakiuchi R; Zhang J; Kojima R; Koroki K; Inoue M; Kanogawa N; Nakagawa R; Kondo T; Ogasawara S; Nakamoto S; Muroyama R; Kato J; Kato N
    Am J Physiol Cell Physiol; 2024 Oct; 327(4):C1150-C1161. PubMed ID: 39250819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.
    Nakagawa T; Matsushima T; Kawano S; Nakazawa Y; Kato Y; Adachi Y; Abe T; Semba T; Yokoi A; Matsui J; Tsuruoka A; Funahashi Y
    Cancer Sci; 2014 Jun; 105(6):723-30. PubMed ID: 24689876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
    Fu R; Jiang S; Li J; Chen H; Zhang X
    Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
    Matsuki M; Hoshi T; Yamamoto Y; Ikemori-Kawada M; Minoshima Y; Funahashi Y; Matsui J
    Cancer Med; 2018 Jun; 7(6):2641-2653. PubMed ID: 29733511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EVA1A reverses lenvatinib resistance in hepatocellular carcinoma through regulating PI3K/AKT/p53 signaling axis.
    Liu X; Gao X; Yang Y; Yang D; Guo Q; Li L; Liu S; Cong W; Lu S; Hou L; Wang B; Li N
    Apoptosis; 2024 Aug; 29(7-8):1161-1184. PubMed ID: 38743191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor and Antiangiogenic Activities of Lenvatinib in Mouse Xenograft Models of Vascular Endothelial Growth Factor-Induced Hypervascular Human Hepatocellular Carcinoma.
    Adachi Y; Matsuki M; Watanabe H; Takase K; Kodama K; Matsui J; Funahashi Y; Nomoto K
    Cancer Invest; 2019; 37(4-5):185-198. PubMed ID: 31006280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression.
    Zhao Z; Zhang D; Wu F; Tu J; Song J; Xu M; Ji J
    J Cell Mol Med; 2021 Jan; 25(1):549-560. PubMed ID: 33210432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells.
    Shi T; Iwama H; Fujita K; Kobara H; Nishiyama N; Fujihara S; Goda Y; Yoneyama H; Morishita A; Tani J; Yamada M; Nakahara M; Takuma K; Masaki T
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis.
    Shi L; Yang F; Luo F; Liu Y; Zhang F; Zou M; Liu Q
    Tumour Biol; 2016 Sep; 37(9):12791-12803. PubMed ID: 27449032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropilin-1 is upregulated in hepatocellular carcinoma and contributes to tumour growth and vascular remodelling.
    Bergé M; Allanic D; Bonnin P; de Montrion C; Richard J; Suc M; Boivin JF; Contrerès JO; Lockhart BP; Pocard M; Lévy BI; Tucker GC; Tobelem G; Merkulova-Rainon T
    J Hepatol; 2011 Oct; 55(4):866-75. PubMed ID: 21338642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chinese herbal formula QHF inhibits hepatocellular carcinoma metastasis via HGF/c-Met signaling pathway.
    Yuan S; Gong Y; Chen R; Du J; Zhang H; Chen T
    Biomed Pharmacother; 2020 Dec; 132():110867. PubMed ID: 33075668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway.
    Yang X; Zhang XF; Lu X; Jia HL; Liang L; Dong QZ; Ye QH; Qin LX
    Hepatology; 2014 May; 59(5):1874-85. PubMed ID: 24259426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells.
    Hamaya S; Fujihara S; Iwama H; Fujita K; Shi T; Nakabayashi R; Mizuo T; Takuma K; Nakahara M; Oura K; Tadokoro T; Mimura S; Tani J; Morishita A; Kobara H; Ono M; Himoto T; Masaki T
    Anticancer Res; 2022 Mar; 42(3):1263-1275. PubMed ID: 35220216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2.
    Ghosh A; Dasgupta D; Ghosh A; Roychoudhury S; Kumar D; Gorain M; Butti R; Datta S; Agarwal S; Gupta S; Krishna Dhali G; Chowdhury A; Schmittgen TD; Kundu GC; Banerjee S
    Cell Death Dis; 2017 Mar; 8(3):e2706. PubMed ID: 28358369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation of a Novel One-Armed Anti-c-Met Antibody with Antitumor Activity Against Hepatocellular Carcinoma.
    Yin Y; Guo J; Teng F; Yu L; Jiang Y; Xie K; Jiang M; Fang J
    Drug Des Devel Ther; 2019; 13():4173-4184. PubMed ID: 31849449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
    Xiang Q; Chen W; Ren M; Wang J; Zhang H; Deng DY; Zhang L; Shang C; Chen Y
    Clin Cancer Res; 2014 Jun; 20(11):2959-70. PubMed ID: 24700742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parecoxib inhibits tumorigenesis and angiogenesis in hepatocellular carcinoma through ERK-VEGF/MMPs signaling pathway.
    Tian L; Huang Y; Liu Y; Liu J; Liu Y
    IUBMB Life; 2024 Nov; 76(11):972-986. PubMed ID: 38873890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications.
    García-Vilas JA; Medina MÁ
    World J Gastroenterol; 2018 Sep; 24(33):3695-3708. PubMed ID: 30197476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation.
    Fernández-Palanca P; Payo-Serafín T; San-Miguel B; Méndez-Blanco C; Tuñón MJ; González-Gallego J; Mauriz JL
    Acta Pharmacol Sin; 2023 May; 44(5):1066-1082. PubMed ID: 36376373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.